QIAGEN N.V. to release results for Q4 2023 and hold webcast

Venlo, The Netherlands, Jan. 11, 2024 (GLOBE NEWSWIRE) — QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) announced plans to release results for the fourth quarter and full year 2023.

Press release date/time: Tuesday, February 6, shortly after 22:05 Frankfurt time / 21:05 London time / 16:05 New York time.

Conference call date/time: Wednesday, February 7, at 15:00 Frankfurt time / 14:00 London time / 09:00 New York time. 

Three options for joining the conference call

  1. Register for call back connection – Click here: Connect me

Service is available 15 minutes before the call starts 

  1. Dial-in by phone

U.S.: +1 646 828 8193
UK: +44 (0)330 165 3655
GER: +49 (0)69 6610 2492
Conference ID: 2206067
To avoid waiting time, please join the event conference 5-10 minutes prior to the start time. 

  1. Access the audio webcast – Click here: Access Webcast 

A conference call replay will be available by using the following link:
https://event.webcasts.com/starthere.jsp?ei=1643464&tp_key=a2e231b651

Contact: IR@qiagen.com

About QIAGEN

QIAGEN N.V., a Netherlands-based holding company, is the leading global provider of Sample to
Insight solutions that enable customers to gain valuable molecular insights from samples containing
the building blocks of life. Our sample technologies isolate and process DNA, RNA and proteins from
blood, tissue and other materials. Assay technologies make these biomolecules visible and ready for
analysis. Bioinformatics software and knowledge bases interpret data to report relevant, actionable 
insights. Automation solutions tie these together in seamless and cost-effective workflows. QIAGEN
provides solutions to more than 500,000 customers around the world in Molecular Diagnostics
(human healthcare) and Life Sciences (academia, pharma R&D and industrial applications, primarily forensics).
As of September 30, 2023, QIAGEN employed more than 6,000 people in over 35 locations worldwide.  
Further information can be found at http://www.qiagen.com.

source: QIAGEN N.V. 
category: Financial

CONTACT: John Gilardi
QIAGEN GmbH
+49 2103 29 11711
IR@qiagen.com

Phoebe Loh
QIAGEN N.V.
+49 2103 29 11457
IR@qiagen.com

Alexandra König
QIAGEN N.V.
+49 2103 29 11709
IR@qiagen.com

Staff

Recent Posts

NuGen Announces Completion of InsuJet(TM) Training with Sol-Millennium(TM) Brazil

Toronto, Ontario--(Newsfile Corp. - July 1, 2024) - NuGen Medical Devices Inc. (TSXV: NGMD) (the…

8 hours ago

Elite Pharmaceuticals, Inc. Reports Financial Results for the Fiscal Year Ended March 31, 2024 and Provides Conference Call Information

Conference Call Scheduled for Tuesday, July 2 at 11:30 AM EDTNorthvale, New Jersey--(Newsfile Corp. -…

8 hours ago

Replicare Attracts Seasoned Leaders From Surgical Telepresence Space

SAN ANTONIO, July 1, 2024 /PRNewswire/ -- Replicare, a leading innovator in remote surgical telepresence…

8 hours ago

MED-LAB ANNOUNCES NEW NAME, LOOK & BUSINESS EXPANSION

MIAMI, July 1, 2024 /PRNewswire/ -- Med-Lab is excited to announce that it is changing…

8 hours ago

Notice of SysInformation Healthcare Services, LLC Data Security Event Which Affected Atlanta Perinatal Consultants, LLP

ATLANTA, July 1, 2024 /PRNewswire/ -- SysInformation Healthcare Services, LLC ("SysInformation"), d/b/a EqualizeRCM, is a professional…

8 hours ago